LEADER 00975nam a22002651i 4500 001 991002050299707536 005 20030328093612.0 008 030925s1969 fr |||||||||||||||||fre 035 $ab12234965-39ule_inst 035 $aARCHE-028258$9ExL 040 $aBiblioteca Interfacoltà$bita$cA.t.i. Arché s.c.r.l. Pandora Sicilia s.r.l. 082 04$a110 100 1 $aBergson, Henri$047460 245 12$aL'evolution creatrice /$cHenri Bergson 250 $a142 ed. 260 $aParis :$bPresses Universitaires de France,$c1969 300 $aXI, 372 p. ;$c22 cm 440 0$aBibliothèque de philosophie contemporaine 650 4$aFilosofia$xFrancia$xSec. 20. 907 $a.b12234965$b02-04-14$c08-10-03 912 $a991002050299707536 945 $aLE002 Fil. XV G 16$g1$i2002000072344$lle002$o-$pE0.00$q-$rl$s- $t0$u0$v0$w0$x0$y.i12618597$z08-10-03 996 $aEvolution crèatrice$929130 997 $aUNISALENTO 998 $ale002$b08-10-03$cm$da $e-$ffre$gfr $h2$i1 LEADER 02492nam 2200385 450 001 9910765706103321 005 20230224152607.0 010 $a3-03842-477-3 024 7 $a10.3390/books978-3-03842-477-2 035 $a(CKB)5400000000000043 035 $a(NjHacI)995400000000000043 035 $a(EXLCZ)995400000000000043 100 $a20230224d2017 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aCurrent Knowledge in Thyroid Cancer - From Bench to Bedside /$fedited by Daniela Gabriele Grimm 205 $aFirst Edition. 210 1$aBasel :$cMDPI,$d2017. 210 4$d©2017 215 $a1 online resource (viii, 212 pages) 320 $aIncludes bibliographical references and index. 330 $aIn recent years, studies in the field of thyroid cancer have been performed in order to identify and verify thyroid specific biomarkers, as well as cancer-specific changes in gene expression patterns and alterations of the protein content. Furthermore, new drugs, small molecules and antibodies were developed and tested in vitro and in vivo. Trials investigated the ratio between therapeutic and adverse effects. Tyrosine kinase inhibitors (TKI) have become a new therapeutic option of both differentiated thyroid cancer and medullary thyroid cancer. In the last few years, new substances for targeted systemic therapy have been approved after their efficacy was demonstrated in Phase III trials. Most of them show a moderate response. However, adverse effects are common. TKI are used in patients with advanced metastatic thyroid cancer that is radioiodine (RAI)-refractory. In this Special Issue, original studies on the pathophysiology, diagnosis, and therapy of thyroid cancer, including genetics, proteomics, metabolomics, molecular and cell biology, will be published. It will also cover reports on patients, providing novel mechanistic insights into the underlying pathogenesis or new aspects that may impact clinical therapy, and recent study results in order to review the current status of new therapy options in thyroid cancer. 606 $aThyroid hormones 615 0$aThyroid hormones. 676 $a612.44 702 $aGrimm$b Daniela Gabriele 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910765706103321 996 $aCurrent Knowledge in Thyroid Cancer ? From Bench to Bedside$92990441 997 $aUNINA